DNA copy number profiling reveals extensive genomic loss in hereditary BRCA1 and BRCA2 ovarian carcinomas
Background: Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gen...
Gespeichert in:
Veröffentlicht in: | British journal of cancer 2013-04, Vol.108 (8), p.1732-1742 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background:
Few studies have attempted to characterise genomic changes occurring in hereditary epithelial ovarian carcinomas (EOCs) and inconsistent results have been obtained. Given the relevance of DNA copy number alterations in ovarian oncogenesis and growing clinical implications of the BRCA-gene status, we aimed to characterise the genomic profiles of hereditary and sporadic ovarian tumours.
Methods:
High-resolution array Comparative Genomic Hybridisation profiling of 53 familial (21
BRCA1
, 6
BRCA2
and 26 non-
BRCA1/2
) and 15 sporadic tumours in combination with supervised and unsupervised analysis was used to define common and/or specific copy number features.
Results:
Unsupervised hierarchical clustering did not stratify tumours according to their familial or sporadic condition or to their
BRCA1/2
mutation status. Common recurrent changes, spanning genes potentially fundamental for ovarian carcinogenesis, regardless of BRCA mutations, and several candidate subtype-specific events were defined. Despite similarities, greater contribution of losses was revealed to be a hallmark of
BRCA1
and
BRCA2
tumours.
Conclusion:
Somatic alterations occurring in the development of familial EOCs do not differ substantially from the ones occurring in sporadic carcinomas. However, some specific features like extensive genomic loss observed in BRCA1/2 tumours may be of clinical relevance helping to identify BRCA-related patients likely to respond to PARP inhibitors. |
---|---|
ISSN: | 0007-0920 1532-1827 |
DOI: | 10.1038/bjc.2013.141 |